- Oversaw and developed the processes for due diligence and deal flow analysis for First Bight Ventures. - Managed projects and maintained CRM, ensuring smooth operations and efficient communication.- Drafted quarterly fund reports and investment memos, showcasing strong analytical and writing skills.- Supported grant writing efforts, contributing to successful funding opportunities.- Led the training and development of new hires.

- Facilitated commercial team integrations through relationship building between legacy Berkeley Lights and IsoPlexis and streamlined knowledge transfer between individuals of the two entities. - Contributed to >$500k in revenue generation in Q2.

- Built and led collaborative, cross-functional teams between account managers, field applications, marketing, and operations to drive customer purchasing decisions leading to over $1,000,000 generated in revenue. - Maintained deep knowledge of IsoPlexis protocols and data including over 120 peer-reviewed publications and 25 protocols to build novel research projects with researchers in cell therapy, immunology, oncology, and autoimmune disorders leading to over 10 poster presentations, papers, and successful grants. - Facilitated continued education and training for over six commercial team hires through science education and supporting engagement with customers. - Consulted on the development, revision, and implementation of processes to maximize revenue generation, such as helping drive $15,000 in revenue within the first 60 days of new installations.

- Co-managed customer engagement opportunities with company leadership across all customer segments within the United States through tailoring messaging and use cases, and setting expectations for best practice to de-risk the technology for potential and new customers during customer meetings.

- Co-managed a team of four biotech consultants developing their proficiency in messaging to the company’s science, understanding the company’s sales process, and how to work alongside the greater sales organization. - Became lead contact for platform implementation across all major and emerging accounts within the United States. - Strategized and oversaw implementation of training curriculum implementation. - Led data analysis for designing and building new projects and tools.

- Built a new process for lead generation using B2B and CRM platforms increasing instrument sales by 25% from Q2 to Q3 2021. - Wrote email sequences for our primary research areas leading to a 10% increase in open and click-through rate. - Performed market and competitor analyses to develop messaging strategies that would best resonate with specific customer segments based on their needs and applications. - Created ROI calculator and graphs highlighting time and labor savings of product application compared to competitor technology to guide messaging in how to sell that specific application.- Led the design process and helped implement training modules for our global sales team through improving scientific foundational knowledge, applying the use of the IsoPlexis platform, and guiding messaging specific to fields such as cell therapy, cancer immunology, neurology, and infectious disease across academic, biotech, and biopharma segments resulting in a 400% increase in instrument sales just from Q3 to Q4 2021.- Conducted bi-weekly product training presentations for new hire onboarding with 8 – 20 attendees on average. - Spoke at World Immunotherapy and Vaccine Congress – West Coast 2021.

Ph.D. training in the laboratory of Francis T.F. Tsai, D.Phil. My dissertation work involved structural, biochemical, and biophysical studies to investigate a protein fragment that may serve as a target to better understand the mammalian stage of the Leishmania parasite - the causative agent of the lesion-forming, neglected tropical disease Leishmaniasis. Skills learned: Project management, communication, technical writing, relationship building, and collaboration

Work through the Consulting Agency in the Texas Medical Center (TMC) Consulting Club: Cancer vaccine project - March 2018. Worked with a group of individuals across the TMC to identify and target biopharmaceutical companies producing cancer vaccines/immunotherapies for Meibai Medical Health. This work included observing trends of targeted cancers, identifying unique and revolutionary technology platforms, and generating metrics to track success of a company.Implementation of AI for FAST Ultrasound examinations - June 2018 This project involved primary and secondary market research at how artificial intelligence and big data technologies can be used in trauma centers. I interviewed emergency room physicians to help identify their needs and desires for improvements to how ultrasound examinations are performed.Online wholesale start-up - June 2019 Led a team to identify financial incentives to improve buyer and seller retention. I researched and suggested a mechanism for cost savings based on geographic proximity between buyers and sellers.

Fellow in the Enventure Research and Innovation Consulting Healthcare (ENRICH) program. Consulted a life-science asset management startup to analyze market competitors, improve pricing models, and identify points-of-entry into the market.

Research in the lab of Somshuvra Mukhopadhyay: Manganese neurotoxicity has been well documented to lead to oxidative stress, mitochondrial dysfunction, and ultimately, neuronal cell death. These neurotoxic effects have since been identified as a Mn-induced Parkinsonism. The majority of individuals experiencing these neurotoxic symptoms were exposed through their occupations, such as mining or steel industry. Recently, a familial-Parkinsonism has been discovered with individuals showing an extremely high concentration of Mn in their blood and in their brain. However, they reported no occupational or high exposure to Mn meaning that their bodies must be retaining the metal that their bodies were ingesting through their everyday diet. Genetic screens on these individuals show mutations in a protein called SLC30A10. But, no function of this protein was known. My lab has since shown that SLC30A10 is a cell-surfaced localized Mn-efflux transporter, and those previously described Parkinson's-like causing mutations block the ability of the transporter to traffic to the cell surface.My work followed this discovery by looking for the transcriptional control of SLC30A10.